Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pimicotinib vs Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor
NCT07707882Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2027
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
A Phase 2 trial of pimicotinib in tenosynovial giant cell tumor (TGCT), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Planned start Oct 2027; status: not yet recruiting.
02
Drugs
pimicotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT07707882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07707882.